(AZE) Azelis - Ratings and Ratios

Exchange: BR • Country: Belgium • Currency: EUR • Type: Common Stock • ISIN: BE0974400328

AZE: Specialty Chemicals, Food Ingredients, Personal Care Products

Azelis Group NV is a leading global distributor of specialty chemicals and food ingredients, operating at the intersection of innovation and supply chain efficiency. The company serves a diverse range of industries, including life sciences (personal care, home care, pharmaceuticals, healthcare, food and nutrition, animal nutrition, agricultural, and environmental solutions) and industrial chemicals (CASE, advanced materials and additives, lubricants, metalworking fluids, electronics, essential and fine chemicals, textiles, leather, and paper markets). This broad market coverage underscores its strategic position as a critical link between chemical manufacturers and end-users.

Headquartered in Antwerp, Belgium, Azelis has built a robust global presence, with operations spanning Europe, the Middle East, and Africa (EMEA), the Americas, and the Asia-Pacific region. Founded in 1996, the company has established itself as a trusted partner in the specialty chemicals sector, known for its technical expertise, regulatory compliance, and ability to deliver tailored solutions. Its extensive network of suppliers and customers, combined with a deep understanding of local markets, enables Azelis to navigate complex supply chains effectively.

From a financial perspective, Azelis Group NV offers an intriguing profile for investors. With a market capitalization of 4.85 billion EUR, the company has demonstrated its ability to scale while maintaining profitability. The trailing P/E ratio of 27.64 reflects its growth trajectory, while the forward P/E of 19.53 suggests expectations of continued expansion. The price-to-book ratio of 1.80 indicates that the market values the company’s intangible assets and growth prospects. Additionally, the price-to-sales ratio of 1.15 highlights its reasonable valuation relative to revenue.

For fund managers and investors, Azelis represents a compelling opportunity to gain exposure to the specialty chemicals and ingredients sector, which is characterized by high margins, innovation-driven demand, and resilience across economic cycles. The company’s balanced geographic diversification and deep sector expertise make it a stable yet growth-oriented investment. Its focus on sustainability and regulatory compliance further aligns with the increasing demand for ESG-conscious investments.

For more information, visit https://www.azelis.com.

Ticker Symbol: AZE Exchange: BR Type: common stock Country Origin: Belgium GICS Sub Industry: Specialty Chemicals Market Cap or AUM: 4852.99M EUR P/E: 27.64 P/E Forward: 19.53 P/B: 1.80 P/S: 1.15

Additional Sources for AZE Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

AZE Stock Overview

Market Cap in USD 5,254m
Sector Basic Materials
Industry Specialty Chemicals
GiC Sub-Industry Specialty Chemicals
IPO / Inception

AZE Stock Ratings

Growth 5y -47.2%
Fundamental 58.0%
Dividend 49.9%
Rel. Strength -8.74
Analysts -
Fair Price Momentum 14.48 EUR
Fair Price DCF 57.58 EUR

AZE Dividends

Dividend Yield 12m 1.25%
Yield on Cost 5y 0.81%
Annual Growth 5y 54.20%
Payout Consistency 93.8%

AZE Growth Ratios

Growth Correlation 3m -55.3%
Growth Correlation 12m -4.6%
Growth Correlation 5y -67.4%
CAGR 5y -13.00%
CAGR/Max DD 5y -0.29
Sharpe Ratio 12m -0.58
Alpha -26.75
Beta 0.652
Volatility 30.39%
Current Volume 211.7k
Average Volume 20d 213.2k
What is the price of AZE stocks?
As of April 02, 2025, the stock is trading at EUR 16.44 with a total of 211,664 shares traded.
Over the past week, the price has changed by -8.11%, over one month by -9.72%, over three months by -14.73% and over the past year by -13.05%.
Is Azelis a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Azelis (BR:AZE) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 58.00 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AZE as of April 2025 is 14.48. This means that AZE is currently overvalued and has a potential downside of -11.92%.
Is AZE a buy, sell or hold?
Azelis has no consensus analysts rating.
What are the forecast for AZE stock price target?
According to ValueRays Forecast Model, AZE Azelis will be worth about 15.9 in April 2026. The stock is currently trading at 16.44. This means that the stock has a potential downside of -3.1%.
Issuer Forecast Upside
Wallstreet Target Price 25.1 52.7%
Analysts Target Price - -
ValueRay Target Price 15.9 -3.1%